Since Erk1/2 and CDK4/6 are key signaling molecules controlling MM cell proliferation and survival, targeting the combination may inhibit both pathways and thereby abrogate both MM cell growth and acquired drug resistance. The gene discussed is MAPK3; the disease is Miyoshi myopathy.